Company Encyclopedia
View More
name
CSL Limited
CSL.AU
News
View More

Australian Shares Start the Week in Red

Australian shares fell as the S&P/ASX 200 dropped 0.2% amid concerns over potential rate hikes by the Reserve Bank of Australia due to strong economic data. Manufacturing PMI hit a three-month high, and ANZ-Indeed Job Ads showed a softening labor market. Financial and healthcare stocks underperformed, with ANZ Group Holdings, National Australia Bank, Westpac Banking Corporation, Sigma Healthcare, Fisher & Paykel Healthcare, and CSL Limited all experiencing declines.

Trading Economics·
US
NABZY
-0.14%
Trading Economics·
US
NABZY
-0.14%

CSL Limited Announces $1.5 Billion U.S. Expansion for Plasma Therapy Manufacturing

CSL Limited plans to invest $1.5 billion in the U.S. over five years to expand plasma therapy manufacturing, creating hundreds of jobs and strengthening the supply chain for critical medicines. This builds on a previous $3 billion investment since 2018, which created over 6,500 jobs. The expansion highlights CSL's commitment to patient care, job creation, and innovation in healthcare.

Reuters·
Reuters·

CSL Limited Announces Cessation of Securities Due to Unmet Conditions

CSL Limited has announced the cessation of 50,194 securities due to unmet conditional rights, impacting its capital structure and stakeholders. The latest analyst rating for CSL stock (AU:CSL) is a Buy with a price target of A$225.00. CSL operates in the biotechnology sector, focusing on innovative medicines and therapies, with a current market cap of A$86.86B and an average trading volume of 1,361,230.

Tip Ranks·
Tip Ranks·

Why CSL (ASX:CSL) Is Down 17.0% After Board Changes and Lowered Revenue Growth Guidance

CSL Limited announced board changes, with Dr. Megan Clark and Ms. Marie McDonald retiring and Mr. Costa Saroukis and Mr. Gordon Naylor joining as new Directors. This transition coincides with a lowered revenue growth guidance for FY26, now projected at 2% to 3%, down from 4% to 5%. The changes introduce uncertainty around execution risks, particularly with ongoing restructuring and the Seqirus demerger. Despite these challenges, CSL anticipates $18.1 billion in revenue and $4.2 billion in earnings by 2028, suggesting a potential fair value of A$280.61, indicating a 60% upside from current prices.

Simplywall·
Simplywall·

CSL Limited Issues Unquoted Securities Under Employee Incentive Scheme

CSL Limited has announced the issuance of 58,360 unquoted securities under an employee incentive scheme, which will not be listed on the ASX until transfer restrictions are lifted. This initiative aims to retain talent and align employee interests with company performance. The latest analyst rating for CSL stock is a Buy, with a price target of A$212.10. CSL is a global biotechnology company focused on innovative biotherapies and influenza vaccines, with a current market cap of A$82.85B.

Tip Ranks·
Tip Ranks·
© 2025 Longbridge｜Disclaimer